Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review

Background: Clozapine is the only Food and Drug Administration (FDA) and National Institute for Care and Excellence (NICE) approved drug for treatment-resistant schizophrenia (TRS). Its potentially life-threatening haematological side effects of neutropaenia and agranulocytosis mandate rigorous moni...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Michelle V. Daniels, Suvira Ramlall
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: AOSIS 2023-10-01
Cyfres:South African Journal of Psychiatry
Pynciau:
clozapine monitoring guidelines
clozapine monitoring guidelines in south africa
treatment-resistant schizophrenia
benign ethnic neutropaenia
benign familial neutropaenia
clozapine-induced neutropaenia
clozapine-induced agranulocytosis
Mynediad Ar-lein:https://sajp.org.za/index.php/sajp/article/view/2039

Rhyngrwyd

https://sajp.org.za/index.php/sajp/article/view/2039

Eitemau Tebyg